7MO Becotarug (JMT101) and osimertinib (Osi) in patients (pts) with platinum-pretreated EGFR exon 20 insertion-mutated (ex20ins) non-small cell lung cancer (NSCLC): Final overall survival (OS) and subgroup analyses from the BECOME phase II study

ESMO Open 2026 Open access

Read full text
Authors: L. Zhang, W.F. Fang, Y. Huang, S. Zhao, Y. Yu, X. Tang, X. Dong, W. Zhuang, F. Luo, Q. Wang, Y. Hu, Q. Chu
+8 more Z. Fu, Y. Yao, X. Ma, C. Ding, X. Wan, Y. Yang, X. Yang, J. Xue
DOI: 10.1016/j.esmoop.2026.106314
Cited by: 2

Abstract

In the phase II BECOME study, Becotarug (Beco) combined with Osi showed promising efficacy and manageable safety in platinum-pretreated EGFR ex20ins-positive NSCLC (ELCC 2024, 137MO). Here, we report the final OS analyses and subgroup efficacy results.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment HER2/EGFR in Cancer Research

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
106314–106314
Publication date
17 March 2026
Language
EN